Bozen, Sud-Tirol, Italy – October 15th, 2012.
Health Robotics reported 16 new contracts in 3Q2012 including 8 I.V. Robots (3 for Oncology and 5 for non-hazardous IVs) and 8 i.v.SOFT agreements, continuing its 3-year supremacy of the global Sterile Compounding Automation market. On a year-to-date basis, YTD 2012 contracts reached an all-time record of 79 new installations over the last 9-month period, a 46% increase over 2011’s 54 new sales on a year-to-date basis. Health Robotics continues to benefit from its decision to transition into a higher-margin direct-sales approach, now accounting for 75%+ of Health Robotics’ revenues, compared to prior years’ dependency on distributors.
Gaspar DeViedma, Health Robotics’ Executive Vice President and Board Member, stated: “I’m very pleased with 3Q2012 results, especially following our record 1Q and 2Q sales and also following Health Robotics’ winning 100% of all worldwide I.V. Robot’s publicly announced purchases in 2010 and 2011. Hospital pharmacists continue to recognize the undeniable fact that Health Robotics’ Second Generation modular architecture of networked medical devices are fully automated, offer 3 to 4 times faster speed/throughput, for less than half the price, size, and weight than its global competitors1, and delivering payback periods/R.O.I. of less than one year.”
During 3Q2012, Health Robotics and/or some of its partners (Rivosem and Grifols) signed 16 new installations
under contract at: Duke University Medical Center, Wyoming Medical Center (Casper), AZ Damiaan (Belgium) Hospital Doctor Negrin (Canary Islands), Mangiagalli’s Neonatology Institute (Milan), La Maddalena Oncology Institute (Palermo, Italy), Campo di Marte Hospital (Lucca, Italy), Trakya University Hospital (Turkey) and Umraniye Egitim Arastirma Hospital (Istanbul).
Mr. DeViedma concluded: “Despite the effects of the global economic crisis in the USA and Western Europe, Health Robotics continues its multi-year market momentum, further demonstrating its resiliency and ability to excel and expand, even in this difficult financial environment. This is a testament of Health Robotics’ proven advantages over its competitors1, and its customers’ published return on investment studies. With the upcoming publication this Fall of two peer-reviewed scientific validation studies for Health Robotics’ Oncology robots in American and European university hospitals, I further expect that the contrast between our proven Oncology technology and that of our competitors’1 will continue to be self-evident.“
1 Competitors: Loccioni-AEA, IHS-RIVA, MDS (now Fresenius Kabi), FHT/Baxa (now Baxter)
About Health Robotics:
Founded in 2006, Health Robotics is the undisputed global leading supplier of life- critical intravenous medication robots, winning 100% of all worldwide I.V. Robot’s publicly announced purchases in 2010 and 2011, and providing over 300 hospital installations in 5 continents with robotics-based technology and clinical software automation solutions. Health Robotics’ world-leading solutions CytoCare® and i.v.STATION® ONCO [hazardous IVs], i.v.STATION® [non-hazardous IVs], i.v.SOFT® [workflow engine for sterile compounding], OMM® [Oncology Medication Management], MEDarchiver® [life-critical clinical information system], and TPNstation® [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals’ growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics’ products help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances’ diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff.
Download in PDF Format :